Gilead to buy cancer drugmaker Immunomedics in $21 billion deal
Gilead Sciences will acquire biotech company Immunomedics in a $21 billion deal that will expand Gilead’s availability of cancer treatments, the companies announced on Sunday.
The deal will provide…
Read More
